Triple-negative　breast　cancer　is　particularly　difficult　to　treat　because　of　its　high　degree　of　malignancy　and　poor　prognosis.　A　fluorescence　resonance　energy　transfer　(FRET)　nanoplatform　plays　a　very　important　role　in　disease　diagnosis　and　treatment　due　to　its　unique　detection　performance.　Combining　the　properties　of　agglomeration-induced　emission　fluorophore　and　FRET　pair,　a　FRET　nanoprobe　(HMSN/DOX/RVRR/PAMAM/TPE)　induced　by　specific　cleavage　was　designed.　First,　hollow　mesoporous　silica　nanoparticles　(HMSNs)　were　used　as　drug　carriers　to　load　doxorubicin　(DOX).　HMSN　nanopores　were　coated　with　the　RVRR　peptide.　Then,　polyamylamine/phenylethane　(PAMAM/TPE)　was　combined　in　the　outermost　layer.　When　Furin　cut　off　the　RVRR　peptide,　DOX　was　released　and　adhered　to　PAMAM/TPE.　Finally,　the　TPE/DOX　FRET　pair　was　constituted.　The　overexpression　of　Furin　in　the　triple-negative　breast　cancer　cell　line　(MDA-MB-468　cell)　can　be　quantitatively　detected　by　FRET　signal　generation,　so　as　to　monitor　cell　physiology.　In　conclusion,　the　HMSN/DOX/RVRR/PAMAM/TPE　nanoprobes　were　designed　to　provide　a　new　idea　for　the　quantitative　detection　of　Furin　and　drug　delivery,　which　is　conducive　to　the　early　diagnosis　and　treatment　of　triple-negative　breast　cancer.　©　2023　American　Chemical　Society.